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ABSTRACT: Synthetic analogues of marine sponge guanidine alkaloids showed in vitro 
antiparasitic activity against Leishmania (L.) infantum and Trypanosoma cruzi. Guanidines 10 
and 11 presented the highest selectivity index when tested against Leishmania. The antiparasitic 
activity of 10 and 11 was investigated in host cells and in parasites. Both compounds induced 
depolarization of mitochondrial membrane potential, upregulation of reactive oxygen species 
(ROS) levels and increased plasma membrane permeability in Leishmania parasites. 
Immunomodulatory assays suggested an NO-independent effect of guanidines 10 and 11 on 
macrophages. The same compounds also promoted anti-inflammatory activity in L. (L.) infantum-
infected macrophages co-cultived with splenocytes, reducing the production of cytokines MCP-1 
and IFN-γ. Guanidines 10 and 11 affect the bioenergetic metabolism of Leishmania, with 
selective elimination of parasites via a host-independent mechanism. 
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Considerable attention has been raised to address the effective cure of neglected tropical 
diseases (NTDs) in the last decade, which globally impact mainly economically disfavored 
nations. These infectious pathogenies, of which most have parasites as the causative agents, have 
spread and now affect population in developed countries as well. Most drugs to treat NTDs were 
developed decades ago and show harmful, even deadly, adverse effects. Therefore, the search for 
new drugs or vaccines to treat human neglected diseases is a priority for the World Health 
Organization and other organizations.1,2 
Two of the deadliest NTDs are leishmaniasis and Chagas disease. Leishmaniasis affects 
12 million people in 98 countries mainly in Africa, Asia, and Latin America.3,4 Two distinct 
human pathological conditions are observed for leishmaniasis, cutaneous and visceral. 
Leishmania (L.) infantum is the etiologic agent of visceral leishmaniasis (VL) in South America 
and southern Europe countries, while Leishmania (L.) donovani is in Asian and African 
countries. Visceral leishmaniasis promoted by L. (L.) infantum is fatal, with a mortality rate of 
100% if untreated.4 Leishmaniasis is included as a target disease by DNDi (Drugs for Neglected 
Diseases initiative) and iOWH (Institute for One World Health).  
Chagas disease is caused by Trypanosoma cruzi as a potentially fatal disorder resulting in 
cardiomegaly and megacolon in about 30% of the patients.5 Chagas disease remains one of the 
most severe public-health problems in 21 countries of Latin America, causing more than 7000 
deaths per year without early and successful antiparasitic treatment. Over 25 million people are at 
risk of infection by T. cruzi and about 7 million people are infected worldwide.1 Chagas disease 
has spread into several European countries and Japan, probably due to population migration. 
Effective treatments for Chagas disease are urgently needed.6  
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Large drug screening campaigns to find new drugs to treat NTDs are currently being 
developed. New criteria for improving the success of clinical drug candidates with potential use 
in NTDs has been recently reviewed.7 While most hit compounds for infectious diseases were 
discovered using phenotypic assays, subsequent optimization efforts need to establish the drug 
target.7 Among various classes of natural and synthetic compounds that present antiparasitic 
activity, guanidines have shown to be of particular interest because of their potent activity and 
suitable pharmacokinetic profile.8-11 Based on the findings recently reported by some of us 
showing potent and selective antileishmanial and antitrypanosomal activity for marine sponge-
derived guanidine alkaloids,11 herein we report the results of the investigation of 18 synthetic 
guanidines as antiparasitic agents against Leishmania and Trypanosoma parasites. The two most 
selective synthetic guanidines active against L. (L.) infantum were further investigated for the 
mechanism of action on the parasites and for their immunomodulatory activity. 
 
RESULTS 
Antileishmanial Activity and Antitrypanosomal Activity. L. (L.) infantum promastigotes were 
incubated for 48 h with guanidines 1-18 and the viability of cells was determined by the MTT 
colorimetric assay. Compounds 1-18 showed IC50 values in the range between 6.6 µM and to 110 
µM. Intracellular L. (L.) infantum amastigotes were also treated with compounds 1-18. The 
observed IC50 values were in the range between 0.8 µM and 49 µM. Miltefosine was used as a 
standard drug (IC50 of 16 µM). T. cruzi trypomastigotes were incubated with the same series of 
compounds for 24 h and the cell viability was determined by the resazurin assay. Guanidines 1-
18 displayed antitrypanosomal activity with IC50 values in the range between 0.9 µM and 88.5 
µM. These results are presented in Table 1. Benznidazole was used as standard drug (IC50 of 
440.7 µM). 
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Determination of the 50% Cytotoxic Concentration (CC50) in Mammalian Cells. Aiming to 
evaluate the mammalian cytotoxicity of compounds 1-19, NCTC cells (clone 929) were 
incubated for 48 h and the cell viability was determined by the colorimetric assay method MTT. 
Guanidines 1-19 showed toxicity with CC50 values in the range between 2.4 µM and >150 µM. 
Miltefosine and benznidazole were used as standard drugs and showed CC50 values of 122.0 µM 
and 469.9 µM, respectively (Table 1). 
Immunomodulatory Potential of Compounds. Quantification of Nitric Oxide (NO). 
Guanidines 10 and 11 showed the highest selectivity index (25 and 20, respectively) as 
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antileishmanial agents (Table 1, Selectivity Index), and were selected for further mechanism of 
action assays. Compounds 10 and 11 were incubated with peritoneal macrophages and the NO 
content was evaluated after 24 h. Both compounds revealed no capacity to upregulate NO 
production (Figure 1). Bacterial lipopolysaccharide (LPS) was used as the positive control. 
Cellular Immune Response of L. (L.) infantum -Infected Macrophages Co-Cultivated with 
Splenocytes. Non-infected and L. (L.) infantum-infected macrophages were treated for 48 h with 
guanidines 10 and 11 and were co-cultived with or without splenocytes. The production of 
cytokines MCP-1, IL-6, IL-10, TNF and IFN-γ was detected by flow cytometry analysis. 
Compound 10 decreased the production of cytokines MCP-1 (p<0.05) and IFN-γ (p<0.05) in both 
non-infected and L. (L.) infantum-infected macrophages. The same result was observed when 
macrophages were co-cultived with or without splenocytes. A similar downregulation effect 
(p<0.001) of MCP-1 was also observed in splenocytes incubated with guanidines 10 and 11. 
However, compounds 10 and 11 did not promote alteration of cytokines TNF, IL-6 and IL-10 
levels (data not shown). The production of cytokine IFN-γ was negatively modulated by 10 and 
11 in non-infected as well as in L. (L.) infantum-infected macrophages co-cultived with 
splenocytes (Figure 2).  
Evaluation of Guanidines 10 and 11 Lethal Action on L. (L.) infantum. Permeability of 
Plasma Membrane. Guanidines 10 and 11 (57 µM and 34 µM, respectively), promoted 
alteration in plasma membrane permeability of Leishmania (L.) infantum promastigotes, 
measured using the fluorescent probe Sytox Green. Compound 11 promoted approximately 64% 
higher fluorescence intensity (Figure 3) after 60 min when compared to untreated parasites 
(p<0.001). Compound 10 also induced significant (p<0.001) increase in fluorescence intensity 
after 60 min of incubation, but less intense than 11 (Figure 3).  
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Evaluation of Mitochondrial Membrane Potential. Alteration of L. (L.) infantum 
mitochondrial membrane potential was investigated in the presence of 10 and 11 (57 µM and 34 
µM, respectively). Promastigotes were incubated with both compounds separately, for 60 min 
and the mitochondrial membrane potential was monitored using the fluorescent probe rhodamine 
123. Both compounds induced a significant reduction (p<0.001) of the fluorescence intensity of 
rhodamine 123 when compared to untreated L. (L.) infantum promastigotes. The 70% 
depolarization intensity caused by both compounds was similar to the level observed with the 
positive control sodium azide (Figure 4).  
Reactive Oxygen Species (ROS) Regulation. Production of ROS by L. (L.) infantum 
promastigotes in the presence of guanidines 10 and 11 was determined using the fluorescent 
probe H2DCF-DA. After 120 min incubation, guanidine 10 promoted significant alteration in L. 
(L.) infantum ROS levels (p<0.001), resulting in a 3-fold higher content than the sodium azide 
positive control. Compound 11 also promoted alteration of ROS levels in L. (L.) infantum, 60% 
higher than in untreated parasites (p<0.05) (Figure 5).  
 
DISCUSSION 
Several guanidine compounds have been evaluated as antiparasitic compounds, and 
showed significant in vitro antileishmanial and antitrypanosomal activity when compared to 
standard drugs.11-18 Based on our recent discovery of a series of alkaloids from the sponge 
Monanchora arbuscula, active against L. (L.) infantum and T. cruzi parasites,11 we evaluated an 
additional series of nineteen synthetic guanidine derivatives against L. (L.) infantum and T. cruzi. 
Among 18 guanidine compounds tested against T. cruzi trypomastigotes, 14 (77%) 
showed activity bellow 100 µM, of which compounds 1, 5, 6, 7, 9, 11 and 17 presented IC50 
values below 10 µM. Guanidines 5, 6, 7, and 9 showed low cytotoxicity and the highest 
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selectivity indexes (SI), between 12 and 28. Guanidine 17 was approximately X-fold more 
effective than the standard drug benznidazole. Guanidines 6 and 7 were about 120-fold more 
effective, presenting a trypanocidal activity observed by the lack of mitochondrial activity 
measured by resazurin. Other guanidine compounds were tested against T. cruzi and showed 
potent activity, in the range between 1 and 10 µM,13 similarly as observed for compounds 1, 5, 6, 
7, 9, 11 and 17. Compound 17 displayed potent antitrypanosomal activity, with an IC50 value of 
0.95 µM. However, the selectivity index was below 10, and cannot attend an important criteria 
for the hit stage.  
Guanidine compounds isolated as natural products and synthetic derivatives have also 
shown potent antileishmanial activity.14-18 Eleven (61%) out of 18 synthetic guanidines herein 
evaluated displayed antileishmanial activity against promastigotes, 9 of which were active against 
L. (L.) infantum intracellular amastigotes bellow 100 µM. Five of these displayed IC50 values 
below 10 µM (1, 10, 11, 12 and 18). Considering the recommendations of the Drugs for 
Neglected Diseases initiative (DNDi) for antileishmanial agents,19 an IC50 <10 µM and selectivity 
index (SI) ≥10 are determinant features for antileishmanial compounds at the hit stage.19,20 
Guanidines 10 and 11 presented SI of 25 and 20, respectively, and were selected for investigation 
of the lethal mechanism of action against Leishmania parasites. 
Due to the complexity of intracellular amastigote defenses, an antileishmanial suitable hit 
compound needs to specifically target the parasite which lives in the acidic parasitophorous 
vacuole inside the macrophage.21 Guanidines 10 and 11 showed more potent antiparasitic activity 
against intracellular amastigotes than to extracellular promastigotes. In order to investigate if the 
antileishmanial activity of 10 and 11 against intracellular amastigotes could be ascribed to an 
immunomodulatory effect in host cells, we evaluated cytokine production by macrophages in the 
presence of guanidines 10 and 11. This approach enables to differentiate compounds that are 
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directly active in the parasite from those that exert antiparasitic effect by an immunomodulatory 
response.22  
Immunomodulators have been investigated as drugs for the clinical treatment of 
leishmaniasis, but with limited efficacy when administered alone.23,24 Guanidines 10 and 11 
caused no upregulation of NO in macrophages. Flow cytometry analysis indicated that 10 and 11 
significantly suppressed the production of IFN-γ and MCP-1 cytokines in the host cell, causing 
no significant alteration of TNF, IL-6 and IL-10 levels. Cytokines play different roles during a 
Leishmania infection in macrophages. In L. (L.) infantum-infected human macrophages, 
treatment with monocyte chemotactic protein chemokine (MCP-1) enhances NO production and 
the antileishmanial activity.25 MCP-1 is a leukocyte activator, related to the production of 
proinflammatory cytokines and microbicidal molecules. It promotes NO release and increased 
parasite killing by T. cruzi-infected macrophages. Upregulation of cytokine IL-6 has been 
associated with a lethal outcome of the disease, preceding death in patients with visceral 
leishmaniasis (VL).26 High levels of IFN-γ, IL-10, and IL-6 are associated with human visceral 
leishmaniasis and with leishmaniasis persistence.27,28  
In addition to the downregulation of inflammatory cytokines induced by guanidines 10 
and 11 in Leishmania-infected macrophages co-cultived with splenocytes, both compounds 
promoted the death of intracellular amastigotes. Attenuation of immune response by 
immunomodulators, such as pentoxyfylline associated with pentavalent antimony, decrease tissue 
inflammation in patients, leading to a curative therapy associated with the decrease of TNF and 
IFN-γ levels.29 These results suggest that guanidines 10 and 11 exert antileishmanial activity by a 
direct effect on parasites, promoting anti-inflammatory modulation in host cells, which might 
contribute to a beneficial prognosis of the disease. 
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Because the antileishmanial activity of guanidines 10 and 11 was associated to other 
mechanisms than merely macrophage activation, we investigated possible intracellular targets in 
Leishmania. Damage to the plasma membrane and mitochondria was then evaluated using 
different fluorescent probes, as mitochondria are unique machinery in protozoan parasites and 
have been shown as a potential target for antiparasitic drugs.30-33 The permeability of the L. (L.) 
infantum plasma membrane was observed using green-fluorescent nuclear and chromosome 
counter stain, which does not enter live cells and exhibits >500-fold fluorescence enhancement 
after binding nucleic acids.34 Both guanidines 10 and 11 increased fluorescence levels, indicating 
the promotion of increased membrane permeabilization within 60 min of incubation.  
The mitochondrial membrane potential is crucial for ATP generation in the respiratory 
chain.33 In contrast to mammalian cells, where the presence of multiple mitochondria ensures 
compensation for functionally impaired ones, trypanosomatids present a single mitochondrion.30 
We investigated the effects of 10 and 11 on Leishmania mitochondria at initial contact. Both 
compounds 10 and 11 induced rapid depolarization of the mitochondrial membrane potential to 
levels similar to the positive control. Amphotericin B, used in the treatment of leishmaniasis, also 
increases permeability of the Leishmania plasma membrane, followed by a rapid decrease in the 
mitochondrial membrane potential.35 Paromomycin significantly decreases the mitochondrial 
membrane potential of Leishmania, indicating that this organelle might be the ultimate drug 
target.31,32 
Leishmania parasites present various defense mechanisms to cope with oxidative stress, 
including expression of antioxidant enzymes such as trypanothione (T(SH)2),
36 superoxide 
dismutase,37 peroxidases,38 trypanothione S-transferase39 and 6-phosphogluconate dehydrogenase 
(6PGDH).40 These enzymes, including iron superoxide dismutase and peroxiredoxin, are located 
in the mitochondria.41 During oxidative stress, excessive amounts of reactive oxygen species 
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(ROS) are produced in the mitochondria. These oxidant components, including superoxide 
radical (O2
•−), hydrogen peroxide (H2O2), hydroxyl radical (HO
•), hypochlorite (OCl−) and 
peroxynitrite (ONOO−), are reactive signaling chemicals that accumulate under pathological 
conditions and lead to oxidative stress caused by dysfunction of the Leishmania mitochondrial 
respiratory chain.42 Guanidine 10 was the most effective compound at enhancing ROS levels in 
Leishmania, while 11 showed a similar effect but to a lesser extent when compared to the positive 
control (sodium azide). Our results are in agreement with the mechanism of action (MoA) of 
other guanidines in protozoan. The antimalarial guanidine proguanil collapse the mitochondrial 
membrane potential of the parasite Plasmodium, the etiologic agent of malaria.45 Considering 
similar effects in mitochondria, it seems probable that the guanidines herein investigated affect 
the respiratory system of Leishmania, leading to parasite death. This outcome may be a useful 
strategy to kill protozoans, as these microorganisms present a single mitochondrion. The capacity 
of these compounds to induce parasite death in the intracellular form without host cell activation 
is another significant outcome, important to provide new drug candidates useful to treat 
immunodeficient patients. 
A series of 18 guanidines tested against T. cruzi and L. (L.) infantum parasites provided an 
elevated number of selective hits, with IC50 values below 10 µM. The two most active 
antileishmanial guanidines, compounds 10 and 11, induce depolarization of the mitochondrial 
membrane potential, promoting a strong alteration of ROS levels in Leishmania parasites. 
Despite an effective detoxification system of these parasites, if not rapidly scavenged the 
accumulated ROS are able to induce strong cellular damage. This effect might contribute to 
oxidative stress induced by guanidines 10 and 11, leading to L. (L.) infantum elimination. A 
computational study was performed to predict Pan-Assay Interference Compounds (PAINS), but 
none of the compounds was predicted as PAINS. The in silico studies, the in vitro potency of 
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guanidines 10 and 11 (<10 µM), a selectivity index >10, as well as the respective MoA against 
Leishmania parasites without affecting host cells, allow us to select these compounds as possible 
hits for future investigations. Further experiments are in progress in order to gather information 
about ADMET properties and in vivo efficacy of compounds 10 and 11. Results will be reported 
in due time. 
 
EXPERIMENTAL SECTION 
Chemicals. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (thiazolyl blue; MTT), 
resazurin (Alamar blue), SYTOX Green, Rhodamine 123 and H2DCFDA were purchased from 
Molecular Probes. Giemsa stain, DMSO and MeOH were obtained from Merck. RPMI-1640 
medium, M-199 medium, Hanks balanced salts, phosphate-buffered saline (PBS), trypan blue 
stain and miltefosine were obtained from Sigma (Brazil). Other reagents were purchased from 
Sigma Aldrich (Brazil). The Cytometric Beads Array (CBA, Mouse Inflammation Kit 
Biosciences) was from Becton Dixon. 
Synthesis of Substrate Compounds. Guanidines 1-18 were tested as antileishmanial and 
antitrypanosomal compounds. Pyrimidine 1, tricyclic guanidines 2-10, pentacyclic guanidine 16 
and tetracyclic guanidine 17 were prepared as previously described.46-52 The naturally occurring 
guanidine alkaloid nitensidine D (18)52 was prepared as its hydrochloride salt in 53% yield by the 
reaction of geranylamine with 1H-pyrazole-1-carboxamidine hydrochloride. 
General Bioassays Procedures. Golden hamsters and BALB/c mice were obtained by the 
animal breeding facility at the Adolfo Lutz Institute-SP, Brazil. The animals were maintained in 
sterilized cages under a controlled environment, and received water and food ad libitum. Animal 
procedures were performed with the approval of the Research Ethics Commission (project 
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number CEUA IAL/Pasteur 02/2011), in agreement with the Guide for the Care and Use of 
Laboratory Animals from the National Academy of Sciences. 
Parasites and Mammalian Cell Maintenance. L. (L.) infantum (MHOM/BR/1972/LD) was 
maintained in Golden hamsters (Mesocricetus auratus) up to approximately 60-70 days post-
infection. Promastigotes were maintained in M-199 medium supplemented with 10% fetal calf 
serum and 0.25% hemin at 24 ºC. Amastigotes were obtained from the spleen of previously 
infected hamsters and purified by differential centrifugation. Macrophages were collected from 
the peritoneal cavity of BALB/c mice by washing them with RPMI-1640 medium supplemented 
with 10% fetal calf serum, and were maintained at 37 ºC in a 5% CO2-humidified incubator. 
Trypomastigotes of T. cruzi (Y strain) were maintained in Rhesus-monkey kidney cells (LLC-
MK2 - ATCC CCL 7), cultivated in RPMI-1640 medium supplemented with 2% fetal calf serum 
at 37 ºC in 5% CO2-humidified incubator. The murine conjunctive cells (NCTC clone 929, 
ATCC) were maintained in RPMI-1640 supplemented with 10 % FBS at 37 oC in a humidified 
atmosphere containing 5 % CO2. NCTC - clone 929 cells were cultivated in M-199 medium, 
supplemented with 10% fetal calf serum at 37 ºC in 5% CO2-humidified incubator. 
Determination of the 50% Inhibitory Concentration (IC50). Promastigotes: Promastigotes in 
late growth-phase (non-stationary at 3 x 107/mL, passage 5) were counted in a hemocytometer 
chamber and seeded at 1 x 106/well, with a final volume of 150 µL. The compounds were 
dissolved in DMSO and diluted in M-199 medium in 96-well microplates, with the highest 
concentration of 150 µM for 48 h at 24 ºC. The parasite viability was determined using the MTT 
colorimetric assay.53 The optical density was read at 570 nm (FilterMax F5 Multi-Mode 
Microplate Reader, Molecular Devices) using control wells without drugs (100% viability) and 
without cells (blank). The control group consisted of promastigotes incubated with 0.5% DMSO. 
Miltefosine was used as a standard drug. Compounds were tested to the highest concentration of 
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100 µM and were reported as NA (not active) when the IC50 value was above this concentration. 
Amastigotes: Peritoneal macrophages were collected from the peritoneal cavity of BALB/c mice, 
and the macrophages were seeded at 1 x 105/well for 24 h in a 16-well slide. Amastigotes were 
prepared as described previously in a 1:10 ratio of macrophages to amastigotes for 24 h at 37 ºC 
5% CO2-humidified incubator. The compounds were incubated with infected macrophages for 
120 h. Miltefosine was used as standard drug. Subsequently, the cells were fixed with MeOH, 
stained with Giemsa and observed using a light microscope. The parasite burden was determined 
by the number of infected macrophages out of 400 cells.20 Compounds were tested to the highest 
concentration of 100 µM and were reported as NA (not active) when the IC50 value was above 
this concentration.  
Trypomastigotes of T. cruzi. Free trypomastigotes were counted in a hemocytometer chamber 
and seeded at 1 x 106 cells per well in 96-well microplates. The compounds were diluted in 
RPMI-1640 medium and incubated in highest concentrations to 150 μM for 24 h at 37 oC in a 5% 
CO2-humidified incubator. The parasite viability was determined using the resazurin (0.011% in 
PBS).54 The optical density was read at 570 nm using control wells without drugs (100% 
viability) and without cells (blank). The control group consisted of trypomastigotes incubated 
with 0.5% DMSO. Benznidazole was used as a standard drug. Compounds were tested to the 
highest concentration of 100 µM and were reported as NA (not active) when the IC50 value was 
above this concentration. 
Cytotoxicity in Mammalian Cells. NCTC cells were counted in a hemocytometer chamber, 
seeded at 6 x 104/well and incubated in highest concentrations to 150 μM for 48 h at 37 oC in a 
5% CO2-humidified incubator. The cell viability was determined using the MTT assay.
53 
Miltefosine was used as standard drug. The selectivity index (SI) was determined using the 
relationship, CC50 against NCTC/IC50 against parasites.  
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Evaluation of Plasma Membrane Permeability. Late growth-phase (non-stationary at 3 x 
107/mL, passage 7) promastigotes were washed in PBS, seeded at 2 x 106/well and incubated with 
1 µM SYTOX Green for 15 min at 24 oC.34 The compounds 10 and 11 were added at their 
respective IC50 values (57 µM and 34 µM, respectively), and the fluorescence was measured 
every 20 min for 60 min total. The maximum permeabilization was obtained with 0.1% Triton X-
100. Fluorescence intensity was determined using a fluorimetric microplate reader (FilterMax F5 
Multi-Mode Microplate Reader, Molecular Devices) with excitation and emission wavelengths of 
485 and 520 nm, respectively. The following internal controls were used in the evaluation: (i) the 
background fluorescence of test compounds, (ii) the possible interference of DMSO, (iii) 
untreated promastigotes, and (iv) medium without any cells. Samples were tested in triplicate.55 
Evaluation of Mitochondrial Membrane Potential. The change in mitochondrial membrane 
potential in intact promastigotes was estimated by measuring rhodamine-123 accumulation.56 
Parasites (2 x 106 promastigotes/mL) were resuspended in Hanks Balanced Salt Solution-Glucose 
(HBSS-Glc) and incubated with the 10 and 11 at the respective IC50 values (57 µM and 34 µM, 
respectively) for 60 min at 25 oC. Subsequently parasites were incubated with rhodamine-123 for 
10 min (0.3 μg/mL, 5 min, 37 oC), washed by centrifugation, and resuspended in HBSS-Glc and 
the fluorescence was determined using a fluorimetric microplate reader with excitation and 
emission wavelengths of 485 and 520 nm, respectively. Sodium azide (10 mM) was used as the 
positive control.57 The following internal controls were used in the evaluation: (i) the background 
fluorescence of test compound, (ii) the possible interference of DMSO, (iii) untreated 
promastigotes, and (iv) medium without any cells. Samples were tested in triplicate. 
Detection of ROS. Promastigotes (2 x 106/well) were washed with HBSS and incubated with 10 
and 11 at the respective IC50 values (57 µM and 34 µM, respectively) for 60 min. H2DCFDA was 
added (5 µM), and the cells were incubated for 15 min. Fluorescence intensity was evaluated 
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using a fluorimetric microplate reader with excitation and emission wavelengths of 485 and 520 
nm, respectively. Sodium azide (10 mM) was used as the positive control.58-60 The following 
internal controls were used in the evaluation: (i) the background fluorescence of test compounds, 
(ii) the possible interference of DMSO, (iii) untreated promastigotes, and (iv) medium without 
any cells. Samples were tested in triplicate. 
Quantification of Nitric Oxide. Nitric oxide (NO) content was measured in the culture 
supernatants from peritoneal macrophages treated with compounds 10 and 11 at the respective 
IC50 values (intracellular amastigote assay= 5 µM and 2 µM, respectively) for 24 h and analyzed 
by Griess assay.61 Results obtained were extrapolated from a standard curve prepared with 
NaNO2 at different concentrations (0 to 400 μM). Bacterial lipopolysaccharide (LPS) (1 µg/mL) 
was used as a positive control. Samples were tested in triplicate. 
Cellular Immune Response Assay. Peritoneal Macrophages Co-Cultived with Splenocytes 
and In Vitro Infection. Peritoneal macrophages were isolated from BALB/c mice and seeded 
into the 24-well plate at 1.5 x 105/well. After 24 h L. (L.) infantum amastigotes were used to 
infect the cells at a 1:10 ratio (macrophage/amastigotes).20 After 24 h infected macrophages were 
co-cultivated with splenocytes at a concentration of 6:1. Preparations were obtained by crushing 
spleens in PBS (pH 7.2). Subsequently, splenocyte suspensions were washed twice with PBS and 
erythrocytes were lysed with Ammonium-Chloride-Potassium (ACK) buffer (0.15 M NH4Cl; 10 
mM KHCO3; 0.1 M Na2EDTA) for 5 min. After washing two times with PBS by centrifugation 
at 4 oC for 10 min, the cells were resuspended in RPMI 1640 medium and 10% heat-inactivated 
fetal calf serum. The viability of the cells used in the experiments was always higher than 85%, 
as measured by trypan blue exclusion. After 48 h with compounds 10 (30 µM) and 11 (15 µM), 
supernatants were collected to perform the cytokine assay. Proteins levels were determined using 
an inflammatory Cytometric Beads Array (CBA) Kit according to the manufacturer's instructions. 
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The concentrations of the released mediators were measured: Interleukin-6 (IL-6), Interleukin- 10 
(IL-10), monocyte chemotactic protein-1 chemokine (MCP-1), Interferon-γ (IFN-γ), Tumor 
Necrosis Factor (TNF), and Interleukin-12p70 (IL-12p70) using flow cytometry. Sham-treated 
macrophages infected with L. (L.) infantum were used as controls. 
Statistical Analysis. The results are represented as the mean and standard deviation of 
replicates samples from at least two independent assays. The IC50 values were calculated using 
sigmoidal dose-response curves using GraphPad Prism 5.0 software. The 95% confidence 
interval is included in parentheses with the analyses. The Test T was used for significance testing 
(p<0.05). 
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Table 1: Antileishmanial/Antitrypanosomal Activities and Mammalian Cytotoxicity of 
Guanidines and the Standard Drugs Benznidazole and Miltefosine.  
Compounds T. cruzi 
trypomastigote
sa 
IC50 (µM) 
95% CI  
L. (L.) infantum 
promastigotesb 
IC50 (µM) 
95% CI  
L. (L.) infantum 
amastigotes 
IC50 (µM) 
95% CI 
NCTC cells 
 
CC50 (µM) 
95% CI  
Selectivity index 
c d 
1 8 (7-9) 42 (36-49) 5 (2-14) 42 (35-51) 8 5 
2 88 (65-119) NA NA >150 ND >2 
3 49 (43-56) NA NA >150 ND >2 
4 22 (21-24) 109 (97-123) NA >150 ND >7 
5 8 (8-8) 53 (45-64) NA 100 (93-107) ND 12 
6 4 (2-9) 59 (47-74) NA 84 (80-88) ND 28 
7 4 (4-7) 48 (39-61) NA 57 (45-71) ND 19 
8 NA NA NA >150 ND ND 
9 4 (4-5) 7 (4-10) 18 (15-21) 65 (58-73) 4 16 
10 41 (36-47) 57 (50-65) 5 (4-7) 138 (115-164) 25 3 
11 9 (8-10) 34 (30-39) 2 (1-4) 45 (42-49) 20 5 
12 NA NA 8 (6-12) >150 >19 ND 
13 NA NA NA >150 ND ND 
14 35 (31-41) 9 (9-10) 19 (6-56)  116 (105-128) 6 3 
15 79 (31-197) 57 (50-65) 24 (23-25) 70 (57-85) 3 0.9 
16 69 (55-86) 47 (40-54) NA 60 (46-79) ND 0.9 
17 0.9 (0.9-10) NA 0.8 (0.3-2) 2 (2-3) 3 2 
18 NA NA 49 (34-72) >150 >3.0 ND 
benznidazole Repetindo ND ND  15 1 
miltefosine ND 16 (15-17) 17 (12-24) 122 (95-157) 7 ND 
 
Cell viability was determined using the resazurina and MTTb assays. IC50: 50% Inhibitory 
Concentration - concentration of compound required to reduce 50% of parasites. CC50: 50% 
Cytotoxic Concentration- concentration of compound that reduces the viability of mammalian 
cells by 50%. All data represent mean values for at least two separate experiments. SI: Selectivity 
Index- ratio of CC50/IC50; c- Leishmania amastigotes; d- Trypanosoma cruzi trypomastigotes. 
95% CI- 95% Confidence Interval. NA- not active to the highest concentration of 100 µM. ND- 
Not determined. 
24 
 
Table of Contents Graphic 
 
 
 
